Guiding the Way for Patients With Lung Cancer: 'He Is my Hero'

The recent FDA approval of Lazcluze plus Rybrevant for EGFR-mutant non-small cell lung cancer is a “big deal” for patients, an oncologist said.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

As a cancer survivor, I’ve found that support from friends and family makes a difference, so here are three ways they can help during survivorship.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.

The Food and Drug Administration approved frontline Lazcluze plus Rybrevant for locally advanced or metastatic non-small cell lung cancer with an EGFR exon 19 deletions or exon 21 L858R substitution mutations.